IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis

Cardiovasc Res. 2009 Apr 1;82(1):59-66. doi: 10.1093/cvr/cvp040. Epub 2009 Jan 30.

Abstract

Aims: We have recently reported that tumour necrosis factor-alpha (TNF-alpha) increases oxidative stress and apoptosis in cardiomyocytes by upregulating p38 mitogen-activated protein (MAP) kinase (MAPK) phosphorylation. Interleukin-10 (IL-10) blocked these effects of TNF-alpha by upregulating extracellular signal-regulated kinase 1/2 (ERK 1/2) MAPK phosphorylation. However, the precise site of this IL-10 action is still unknown, and this is investigated in the present study.

Methods and results: Cardiomyocytes isolated from adult Sprague-Dawley rats were exposed to TNF-alpha (10 ng/mL), IL-10 (10 ng/mL), and IL-10+TNF-alpha (ratio 1) for 4 h. Hydrogen peroxide and antioxidant trolox were used as positive controls. Exposure to TNF-alpha resulted in an increase in the production of reactive oxygen species, the number of apoptotic cells, caspase-3 activation, and poly-ADP ribose polymerase (PARP) cleavage. Increased oxidative stress by using hydrogen peroxide also caused apoptosis. The changes due to TNF-alpha were associated with an increase in the inhibitor of kappaB kinase (IKK) and nuclear factor kappa-B (NF kappaB) phosphorylation. IL-10 by itself had no effect, but it prevented the above mentioned TNF-alpha-induced changes. Trolox also mitigated TNF-alpha induced changes. Pre-exposure of cells to an IKK inhibitor (PS-1145) prevented TNF-alpha-induced caspase-3 and PARP cleavage. Inhibition of ERK 1/2 MAPK with PD98059 attenuated the protective role of IL-10 against TNF-alpha-induced activation of IKK and NF kappaB as well as cardiomyocyte apoptosis.

Conclusion: The present study shows that TNF-alpha-induced activation of the NF kappaB pathway plays a critical role in cardiomyocyte apoptosis. IL-10 prevents TNF-alpha-induced NF kappaB activation and pro-apoptotic changes in cardiomyocytes by inhibiting IKK phosphorylation through the activation of ERK 1/2 MAPK.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Apoptosis* / drug effects
  • Caspase 3 / metabolism
  • Cells, Cultured
  • Chromans / pharmacology
  • Enzyme Activation
  • Flavonoids / pharmacology
  • Heterocyclic Compounds, 3-Ring / pharmacology
  • Hydrogen Peroxide / pharmacology
  • I-kappa B Kinase / antagonists & inhibitors
  • I-kappa B Kinase / metabolism
  • Interleukin-10 / metabolism*
  • Male
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / immunology*
  • Myocytes, Cardiac / pathology
  • NF-kappa B / metabolism*
  • Oxidants / pharmacology
  • Oxidative Stress
  • Phosphorylation
  • Poly(ADP-ribose) Polymerases / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Pyridines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Antioxidants
  • Chromans
  • Flavonoids
  • Heterocyclic Compounds, 3-Ring
  • NF-kappa B
  • Oxidants
  • PS1145
  • Protein Kinase Inhibitors
  • Pyridines
  • Reactive Oxygen Species
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Hydrogen Peroxide
  • Poly(ADP-ribose) Polymerases
  • I-kappa B Kinase
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Casp3 protein, rat
  • Caspase 3
  • 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one